The mainstay of the treatment of HRS-AKI is to improve renal blood flow by increasing effective circulation volume through the use of albumin and systemic vasoconstrictors to counteract arterial and splanchnic vasodilation [10,23]. This evidence concerns the gene ALB and acute kidney injury.